Omeros CorporationOMER stock score: 57/100
$14.01 · -3.71% · Scored Nov 19, 2026
- Technical
- 53
- Fundamental
- 58
- News
- 52
The reading
Omeros (OMER) scores 57 out of 100, which reads neutral, higher than 69% of Healthcare stocks and 68% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 58, technicals 53.
Among the fundamentals, Price Target at 100 and Profit Margins at 100 score highest, while Earnings Quality (Annual) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 26 and contrarian oscillators 71 — a split worth reading before trusting the technical total.
News sentiment is neutral at 52; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 53 to 61, and it is down 3 points over the period.
About Omeros
Omeros (OMER) is a biopharmaceutical company focused on drugs that target the complement system, part of the immune system. Its first approved product, Yartemlea (narsoplimab), is an antibody that blocks a key enzyme of the lectin pathway of complement. The FDA approved it for hematopoietic stem cell transplant-associated thrombotic microangiopathy, a serious complication of stem cell transplants, in adults and children, and the company has also sought approval in Europe. Omeros sells Yartemlea to transplant centers and hospitals in the United States, and those sales are its main source of product revenue. The company sold global rights to zaltenibart, a complement inhibitor for rare blood and kidney diseases, to Novo Nordisk for an upfront payment plus potential milestones and royalties. It funds earlier-stage programs from product sales, deal proceeds and capital raised from investors.
In transplant-associated thrombotic microangiopathy, Yartemlea competes mainly with off-label use of complement inhibitors from AstraZeneca’s Alexion unit, along with supportive care. Its edge rests on being the first approved therapy for the condition, a mechanism that targets the lectin pathway specifically and a label that carries no boxed warning. Investors who follow OMER stock tend to watch the U.S. launch of Yartemlea, including uptake at transplant centers, reimbursement and quarterly sales. Regulatory decisions outside the United States are closely followed. Zaltenibart milestones, debt obligations and cash burn are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward OMER’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
58Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Profit margins show what percentage of revenue becomes profit.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Holding it back
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
5-year earnings growth evaluates long-term profit trajectory and consistency.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
31 weighted scorers; 8 had no data today and are left out rather than counted as zero.
Technical · daily
32Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
The price change over the last 52 weeks.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Weighted Moving Average (50-period) tracks the intermediate trend with more weight on recent prices than a simple 50-period average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 52
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 33 | 1 |
| Daily | 32 | 3 |
| Weekly | 56 | 2 |
| Monthly | 70 | 2 |
| Quarterly | 74 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 57 |
| Nov 18, 2026 | 58 |
| Nov 17, 2026 | 57 |
| Nov 16, 2026 | 58 |
| Nov 15, 2026 | 59 |
| Nov 14, 2026 | 59 |
| Nov 13, 2026 | 60 |
| Nov 12, 2026 | 61 |
| Nov 11, 2026 | 57 |
| Nov 10, 2026 | 55 |
| Nov 8, 2026 | 53 |
| Nov 7, 2026 | 53 |
| Nov 6, 2026 | 53 |
| Nov 5, 2026 | 54 |
| Nov 4, 2026 | 58 |
| Nov 3, 2026 | 59 |
| Nov 2, 2026 | 57 |
| Nov 1, 2026 | 57 |
| Oct 30, 2026 | 57 |
| Oct 29, 2026 | 59 |
| Oct 28, 2026 | 58 |
| Oct 27, 2026 | 56 |
| Oct 26, 2026 | 55 |
| Oct 25, 2026 | 54 |
| Oct 24, 2026 | 54 |
| Oct 23, 2026 | 55 |
| Oct 22, 2026 | 54 |
| Oct 21, 2026 | 54 |
| Oct 20, 2026 | 54 |
| Oct 19, 2026 | 54 |
| Oct 18, 2026 | 54 |
| Oct 17, 2026 | 54 |
| Oct 16, 2026 | 54 |
| Oct 15, 2026 | 56 |
| Oct 14, 2026 | 56 |
| Oct 13, 2026 | 58 |
| Oct 12, 2026 | 59 |
| Oct 11, 2026 | 60 |
| Oct 10, 2026 | 60 |
| Oct 9, 2026 | 60 |
| Oct 8, 2026 | 59 |
| Oct 7, 2026 | 58 |
| Oct 6, 2026 | 57 |
| Oct 5, 2026 | 58 |
| Oct 4, 2026 | 57 |
| Oct 3, 2026 | 57 |
| Oct 2, 2026 | 56 |
| Oct 1, 2026 | 57 |
| Sep 30, 2026 | 58 |
| Sep 29, 2026 | 58 |
| Sep 28, 2026 | 58 |
| Sep 27, 2026 | 60 |
| Sep 26, 2026 | 60 |
| Sep 25, 2026 | 60 |
| Sep 24, 2026 | 60 |
| Sep 23, 2026 | 61 |
| Sep 22, 2026 | 61 |
| Sep 21, 2026 | 58 |
| Sep 20, 2026 | 57 |
| Sep 19, 2026 | 57 |
| Sep 18, 2026 | 58 |
| Sep 17, 2026 | 59 |
| Sep 16, 2026 | 57 |
| Sep 15, 2026 | 56 |
| Sep 14, 2026 | 56 |
| Sep 13, 2026 | 58 |
| Sep 12, 2026 | 58 |
| Sep 11, 2026 | 57 |
| Sep 10, 2026 | 57 |
| Sep 9, 2026 | 60 |
| Sep 8, 2026 | 60 |
| Sep 7, 2026 | 60 |
| Sep 6, 2026 | 60 |
| Sep 5, 2026 | 60 |
| Sep 4, 2026 | 60 |
| Sep 3, 2026 | 60 |
| Sep 2, 2026 | 60 |
| Sep 1, 2026 | 59 |
| Aug 31, 2026 | 59 |
| Aug 30, 2026 | 59 |
| Aug 29, 2026 | 59 |
| Aug 28, 2026 | 59 |
| Aug 27, 2026 | 60 |
| Aug 26, 2026 | 59 |
| Aug 25, 2026 | 60 |
| Aug 24, 2026 | 61 |
| Aug 23, 2026 | 60 |
Key facts
- Market cap
- $1.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 2.99
- Risk grade (1–10)
- 8
- Next earnings
- Nov 16, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| VOR Vor Biopharma | $1.1B | 43 |
| NKTR Nektar Therapeutics | $1.1B | 27 |
| INBX Inhibrx Biosciences | $1.1B | 38 |
| ANRO Alto Neuroscience | $1.1B | 36 |
| DRTS Alpha Tau Medical | $1.0B | 30 |
| JBIO Jade Biosciences | $1.0B | 36 |
Questions
What is OMER's stock rating today?
OMER scores 57/100 (Neutral) as of Nov 19, 2026: technical 53, fundamental 58, and news sentiment 52, which is shown but not counted. Scores are recomputed every night.
What does Omeros do?
Omeros (OMER) is a biopharmaceutical company focused on drugs that target the complement system, part of the immune system. Its first approved product, Yartemlea (narsoplimab), is an antibody that blocks a key enzyme of the lectin pathway of complement.
Is OMER stock a buy?
The score is not a buy or sell recommendation. A 57 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the OMER score calculated?
93 weighted scorers feed it today: 31 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/omer/"><img src="https://stocksscores.com/stocks/omer/badge.svg" alt="OMER stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/omer/)